



Universiteit
Leiden
The Netherlands

The path to individualised breast cancer screening

Lakeman, I.M.M.

Citation

Lakeman, I. M. M. (2022, June 14). *The path to individualised breast cancer screening*. Retrieved from <https://hdl.handle.net/1887/3420638>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3420638>

Note: To cite this publication please use the final published version (if applicable).

The path to individualised breast cancer screening

Inge M.M. Lakeman

The path to individualised breast cancer screening

Thesis, department of Human Genetics and Clinical Genetics, Leiden University Medical Center, Leiden, the Netherlands.

ISBN: 978-94-6423-798-6

Cover photo: Jan Lakeman

Cover design: Inge Lakeman

Layout and printing: Vera van Beek – ProefschriftMaken || www.proefschriftmaken.nl

The research presented in this thesis was financially supported by the Dutch Cancer Society (grant number: KWF UL2014-7473).

Financial support for publication of this thesis was kindly provided by the department of Human Genetics of the Leiden University Medical Center, and ChipSoft.

© copyright Inge M.M. Lakeman, 2022, the Netherlands.

All rights reserved. No part of this thesis may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, without the prior permission of the author.

The path to individualised breast cancer screening

Proefschrift

ter verkrijging van
de graad van doctor aan de Universiteit Leiden,
op gezag van rector magnificus prof.dr.ir. H. Bijl,
volgens besluit van het college voor promoties
te verdedigen op dinsdag 14 juni 2022
klokke 11.15 uur

door

Inge Margaretha Maria Lakeman
geboren te Hoorn
in 1987

Promotores

prof. dr. P. Devilee

prof. dr. C.J. van Asperen

Co-promotor

dr. M. Rodriguez - Girondo

Promotiecommissie

prof. dr. ir. M.K. Schmidt

prof. dr. A.G. Uitterlinden

prof. dr. R. Schmutzler

dr. M.A. Adank

Erasmus Medical Center

University of Cologne

The Netherlands Cancer Institute -

Antoni van Leeuwenhoek hospital

Contents

Chapter 1	General introduction	7
Chapter 2	Addition of a 161-SNP polygenic risk score to family history-based risk prediction: impact on clinical management in non-BRCA1/2 breast cancer families <i>Lakeman IMM, et al. Journal of Medical Genetics 2019;56:581-589</i>	37
Chapter 3	Clinical applicability of the Polygenic Risk Score for breast cancer risk prediction in familial cases <i>Lakeman IMM, et al. Submitted</i>	63
Chapter 4	Validation of the BOADICEA model and a 313-variant polygenic risk score for breast cancer risk prediction in a Dutch prospective cohort <i>Lakeman IMM, et al. Genetics in Medicine 2020;22:1803-1811</i>	103
Chapter 5	The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous <i>BRCA1</i> or <i>BRCA2</i> pathogenic variant <i>Lakeman IMM, et al. Genetics in Medicine 2021;23:1726-1737</i>	135
Chapter 6	Comprehensive breast cancer risk prediction for women from non-BRCA1/2 breast cancer families – an observational pilot study in one Dutch medical centre	167
Chapter 7	Discussion and future perspectives	181
Chapter 8	Nederlandse samenvatting List of publications Curriculum Vitae Dankwoord	201 211 214 215
Appendix 1	Argumenten voor centrale toetsing niet WMO-plichtig multicenter onderzoek	219